{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:40:19Z","timestamp":1790476819750,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.canlet.2021.06.002","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T04:37:53Z","timestamp":1623386273000},"page":"78-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Dysregulated KRAS gene-signaling axis and abnormal chromatin remodeling drive therapeutic resistance in heterogeneous-sized circulating tumor cells in gastric cancer patients"],"prefix":"10.1016","volume":"517","author":[{"given":"Yang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youping","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedbar S.","family":"Khadka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy Dandan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanyang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Ping","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2021.06.002_bib1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41568-019-0180-2","article-title":"Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells","volume":"19","author":"Keller","year":"2019","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2021.06.002_bib2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrclinonc.2013.253","article-title":"Molecular analysis of circulating tumour cells-biology and biomarkers","volume":"11","author":"Krebs","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2021.06.002_bib3","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1126\/science.1228522","article-title":"Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition","volume":"339","author":"Yu","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.canlet.2021.06.002_bib4","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav4275","article-title":"Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis","volume":"5","author":"Liu","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2021.06.002_bib5","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nrclinonc.2015.208","article-title":"Revisiting tumour aneuploidy - the place of ploidy assessment in the molecular era","volume":"13","author":"Danielsen","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2021.06.002_bib6","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/nrc1714","article-title":"On the road to cancer: aneuploidy and the mitotic checkpoint","volume":"5","author":"Kops","year":"2005","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2021.06.002_bib7","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/embor.2012.61","article-title":"Cancer chromosomal instability: therapeutic and diagnostic challenges","volume":"13","author":"McGranahan","year":"2012","journal-title":"EMBO Rep."},{"key":"10.1016\/j.canlet.2021.06.002_bib8","doi-asserted-by":"crossref","first-page":"6594","DOI":"10.18632\/oncotarget.2175","article-title":"Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer","volume":"5","author":"Li","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2021.06.002_bib9","doi-asserted-by":"crossref","first-page":"5261","DOI":"10.1158\/1078-0432.CCR-18-1205","article-title":"Evolutionary expression of HER2 conferred by chromosome aneuploidy on circulating gastric cancer cells contributes to developing targeted and chemotherapeutic resistance","volume":"24","author":"Li","year":"2018","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2021.06.002_bib10","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1158\/1541-7786.MCR-19-0077","article-title":"KRAS activation in gastric adenocarcinoma stimulates epithelial-to-mesenchymal transition to cancer stem-like cells and promotes metastasis","volume":"17","author":"Yoon","year":"2019","journal-title":"Mol. Canc. Res."},{"key":"10.1016\/j.canlet.2021.06.002_bib11","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1634\/theoncologist.2017-0379","article-title":"Genomic profiling of HER2-positive gastric cancer: PI3K\/Akt\/mTOR pathway as predictor of outcomes in HER2-positive advanced gastric cancer treated with trastuzumab","volume":"23","author":"Diaz-Serrano","year":"2018","journal-title":"Oncol."},{"key":"10.1016\/j.canlet.2021.06.002_bib12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.gde.2010.10.010","article-title":"Utilizing circulating tumor cells: challenges and pitfalls","volume":"21","author":"Attard","year":"2011","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.canlet.2021.06.002_bib13","doi-asserted-by":"crossref","first-page":"861341","DOI":"10.1155\/2010\/861341","article-title":"Cytomorphology of circulating colorectal tumor cells:a small case series","volume":"2010","author":"Marrinucci","year":"2010","journal-title":"J. Oncol."},{"key":"10.1016\/j.canlet.2021.06.002_bib14","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ccr.2013.03.004","article-title":"Tumor dissemination: an EMT affair","volume":"23","author":"Thiery","year":"2013","journal-title":"Canc. Cell"},{"key":"10.1016\/j.canlet.2021.06.002_bib15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.canlet.2019.10.041","article-title":"PD-L1(+) aneuploid circulating tumor endothelial cells (CTECs) exhibit resistance to the checkpoint blockade immunotherapy in advanced NSCLC patients","volume":"469","author":"Zhang","year":"2020","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2021.06.002_bib16","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1002\/cncr.29455","article-title":"Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases","volume":"121","author":"Chen","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2021.06.002_bib17","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.canlet.2017.10.004","article-title":"Quantified postsurgical small cell size CTCs and EpCAM(+) circulating tumor stem cells with cytogenetic abnormalities in hepatocellular carcinoma patients determine cancer relapse","volume":"412","author":"Wang","year":"2018","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2021.06.002_bib18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/bjc.2015.417","article-title":"Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer","volume":"114","author":"Li","year":"2016","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.canlet.2021.06.002_bib19","first-page":"579","article-title":"Aneuploidy of chromosome 8 in circulating tumor cells correlates with prognosis in patients with advanced gastric cancer","volume":"28","author":"Li","year":"2016","journal-title":"Chin. J. Canc. Res."},{"key":"10.1016\/j.canlet.2021.06.002_bib20","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41596-018-0103-9","article-title":"Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap","volume":"14","author":"Reimand","year":"2019","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.canlet.2021.06.002_bib21","doi-asserted-by":"crossref","first-page":"W191","DOI":"10.1093\/nar\/gkz369","article-title":"g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update)","volume":"47","author":"Raudvere","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2021.06.002_bib22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.semcancer.2018.03.005","article-title":"Ras and Rap1: a tale of two GTPases","volume":"54","author":"Shah","year":"2019","journal-title":"Semin. Canc. Biol."},{"key":"10.1016\/j.canlet.2021.06.002_bib23","doi-asserted-by":"crossref","first-page":"5810","DOI":"10.1158\/0008-5472.CAN-16-0716","article-title":"Chromatin-remodeling complex SWI\/SNF controls multidrug resistance by transcriptionally regulating the drug efflux pump ABCB1","volume":"76","author":"Dubey","year":"2016","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2021.06.002_bib24","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1126\/science.aab0917","article-title":"RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance","volume":"349","author":"Miyamoto","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.canlet.2021.06.002_bib25","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41467-017-00196-1","article-title":"Molecular characterization of breast cancer CTCs associated with brain metastasis","volume":"8","author":"Boral","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2021.06.002_bib26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/1479-5876-11-297","article-title":"The chromatin remodelling component SMARCB1\/INI1 influences the metastatic behavior of colorectal cancer through a gene signature mapping to chromosome 22","volume":"11","author":"Pancione","year":"2013","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2021.06.002_bib27","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.trecan.2017.08.006","article-title":"KRAS alleles: the devil is in the detail","volume":"3","author":"Haigis","year":"2017","journal-title":"Trends Canc."},{"key":"10.1016\/j.canlet.2021.06.002_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aay6013","article-title":"RAS, wanted dead or alive: advances in targeting RAS mutant cancers","volume":"13","author":"Stalnecker","year":"2020","journal-title":"Sci. Signal."},{"key":"10.1016\/j.canlet.2021.06.002_bib29","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s10120-019-00972-6","article-title":"KRAS status is related to histological phenotype in gastric cancer: results from a large multicentre study","volume":"22","author":"Hewitt","year":"2019","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.canlet.2021.06.002_bib30","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-17-2781","article-title":"Biomarkers of primary resistance to trastuzumab in HER2-positive metastatic gastric cancer patients: the AMNESIA case-control study","volume":"24","author":"Pietrantonio","year":"2018","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2021.06.002_bib31","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1038\/oncsis.2015.1","article-title":"Rap1 is indispensable for TRF2 function in etoposide-induced DNA damage response in gastric cancer cell line","volume":"4","author":"Li","year":"2015","journal-title":"Oncogenesis"},{"key":"10.1016\/j.canlet.2021.06.002_bib32","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nrclinonc.2017.40","article-title":"Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges","volume":"14","author":"Bradley","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2021.06.002_bib33","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1038\/emm.2013.115","article-title":"Phosphoproteomic analysis identifies activated MET-axis PI3K\/AKT and MAPK\/ERK in lapatinib-resistant cancer cell line","volume":"45","author":"Lee","year":"2013","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.canlet.2021.06.002_bib34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41419-017-0132-2","article-title":"Dual PI3K\/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K\/Akt\/mTOR pathway","volume":"9","author":"Chen","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2021.06.002_bib35","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/onc.2009.4","article-title":"The SWI\/SNF complex and cancer","volume":"28","author":"Reisman","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2021.06.002_bib36","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1158\/0008-5472.CAN-15-0380","article-title":"Genome-wide identification and characterization of novel factors conferring resistance to topoisomerase II poisons in cancer","volume":"75","author":"Wijdeven","year":"2015","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2021.06.002_bib37","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","article-title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study","volume":"21","author":"Gounder","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2021.06.002_bib38","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521002858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521002858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:57:50Z","timestamp":1759593470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383521002858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":38,"alternative-id":["S0304383521002858"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2021.06.002","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dysregulated KRAS gene-signaling axis and abnormal chromatin remodeling drive therapeutic resistance in heterogeneous-sized circulating tumor cells in gastric cancer patients","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2021.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}